(1.07%) 5 072.02 points
(1.00%) 38 282 points
(1.62%) 15 858 points
(0.18%) $79.14
(5.59%) $2.04
(0.25%) $2 316.80
(0.66%) $26.93
(1.04%) $964.80
(-0.09%) $0.932
(-0.32%) $10.99
(-0.09%) $0.798
(-1.34%) $92.01
Quarter results today
(bmo 2024-05-02)
Expected move: +/- 8.49%
-0.33% $ 57.53
@ $58.15
Emitido: 14 feb 2024 @ 15:11
Retorno: -1.07%
Señal anterior: feb 13 - 09:30
Señal anterior:
Retorno: 4.68 %
Live Chart Being Loaded With Signals
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need...
Stats | |
---|---|
Volumen de hoy | 146 350 |
Volumen promedio | 361 314 |
Capitalización de mercado | 2.07B |
EPS | $-1.340 ( 2024-03-01 ) |
Próxima fecha de ganancias | ( $-1.350 ) 2024-05-30 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -11.06 |
ATR14 | $0.0840 (0.15%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-23 | Seehra Jasbir | Buy | 125 000 | Employee Stock Option (right to buy) |
2024-02-13 | Seehra Jasbir | Buy | 125 000 | Employee Stock Option (right to buy) |
2024-02-13 | Regnante Keith | Buy | 40 000 | Employee Stock Option (right to buy) |
2024-02-13 | Rovaldi Christopher | Buy | 150 000 | Employee Stock Option (right to buy) |
2024-02-13 | Cooper Simon Peter | Buy | 40 000 | Employee Stock Option (right to buy) |
INSIDER POWER |
---|
67.74 |
Last 96 transactions |
Buy: 1 546 013 | Sell: 365 314 |
Volumen Correlación
Keros Therapeutics Inc Correlación
10 Correlaciones Más Positivas | |
---|---|
PRAX | 0.919 |
CDNA | 0.904 |
HNNA | 0.894 |
RPAY | 0.889 |
TTEC | 0.888 |
EWTX | 0.883 |
SMSI | 0.882 |
SRAX | 0.879 |
ANNX | 0.876 |
LPCN | 0.874 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Keros Therapeutics Inc Correlación - Moneda/Commodity
Keros Therapeutics Inc Finanzas
Annual | 2023 |
Ingresos: | $151 000 |
Beneficio Bruto: | $-664 000 (-439.74 %) |
EPS: | $-5.20 |
FY | 2023 |
Ingresos: | $151 000 |
Beneficio Bruto: | $-664 000 (-439.74 %) |
EPS: | $-5.20 |
FY | 2022 |
Ingresos: | $0 |
Beneficio Bruto: | $-1.62M (0.00 %) |
EPS: | $-4.15 |
FY | 2021 |
Ingresos: | $20.10M |
Beneficio Bruto: | $0.00 (0.00 %) |
EPS: | $-2.52 |
Financial Reports:
No articles found.
Keros Therapeutics Inc
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico